Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial
Waldron-Lynch, F., Kareclas, P., Irons, K., Walker, N. M., Mander, A., Wicker, L. S., Todd, J. A., Bond, S.Volume:
4
Language:
english
Journal:
BMJ Open
DOI:
10.1136/bmjopen-2014-005559
Date:
June, 2014
File:
PDF, 881 KB
english, 2014